...Wade Walke Well, I'd like to thank TD Cowen for inviting Ionis to present today at their conference. I am Wade Walke, I'm the Head of Investor Relations at Ionis Pharmaceuticals. I would like to remind everyone that I will be making forward-looking statements, and I would encourage you to take a look at the risk factors that we've outlined in our SEC filings to get a better idea of the context. The Ionis of today is not the same company that I joined over 10 years ago. There's many key differences. Back then, Ionis was really focused on building an R&D engine, which still has today, one of the most astounding R&D engines I've ever seen. And -- but back then, they were focused on building a genetic medicines company that was focused on building a new platform technology for drug discovery, focused on antisense. And they did a remarkable job in that endeavor. I would just point you to SPINRAZA as an example of a blockbuster drug that came out of that effort. But back then, we were really...
